Side effects are generally mild and covered in the AOD-9604 side effects article
Authors relationships and activities VSS has received conference travel support from Merck
SURMOUNT-5 Head-to-Head In 2025, Eli Lilly published the SURMOUNT-5 trial directly comparing tirzepatide (15 mg) and semaglutide (2.4 mg) in adults with obesity over 72 weeks
Pricing Disclaimer: All prices, subscription tiers, and plan structures mentioned were accurate at the time of publication (April 2026) and are subject to change without notice
According to a SELECT clinical trial, adults who were overweight or obese and had CKD without diabetes received 2.4 mg of semaglutide weekly for 104 weeks
Naturally, these are all things you want to avoid, but when you add a GLP-1 in the mix, you may have additional challenges with your appetite and food intake